ACR 125 is a ceremonial, nonbinding concurrent resolution that designates a month in 2026 to raise awareness of Chiari malformations and recites basic medical facts and research activity. It includes standard preamble “whereas” clauses summarizing symptoms, related conditions, and ongoing NIH/NINDS research, and directs the Assembly’s Chief Clerk to transmit copies of the resolution to the author for distribution.
The measure does not create new programs, appropriate funds, or impose regulatory duties. Its practical effect is symbolic: it gives patient advocates, clinicians, and health nonprofits a state-level acknowledgement they can use for public education, fundraising, and coordination of events — without creating state-funded obligations or new legal authorities.
At a Glance
What It Does
ACR 125 adopts a nonbinding statement of legislative recognition through preamble recitals about Chiari malformation and a brief resolved clause directing the Chief Clerk to send copies to the author. The resolution contains no appropriations, mandates, or regulatory instructions.
Who It Affects
Patients with Chiari malformation, family caregivers, rare-disease advocacy organizations, neurosurgery and neurology clinics, and research centers that track condition prevalence and outreach opportunities are the primary audiences. State agencies are not assigned new duties but may be asked informally to participate in outreach.
Why It Matters
Formal recognition creates a predictable date for outreach campaigns, can strengthen advocacy messaging, and offers a public record that patient groups can cite in grant applications and communications. It also signals legislative awareness of the condition to constituents and federal research bodies mentioned in the recitals.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
ACR 125 is a short, ceremonial resolution that frames Chiari malformation as a public-health issue and memorializes legislative attention to it. The bill’s text is built almost entirely from preamble clauses that summarize the medical profile of Chiari malformation — when symptoms typically appear, the kinds of neurologic and structural comorbidities that often accompany it, and the clinical symptoms patients may experience.
The bill also cites federal research activity by the National Institute of Neurological Disorders and Stroke as background.
The operative language is minimal and procedural. Rather than creating programs or funding streams, the resolution uses the legislature’s conventional vehicle for recognition: it records awareness intent and instructs the Assembly’s Chief Clerk to provide copies of the adopted resolution to the author for further distribution.
Because it is a concurrent resolution, it is intended as a statement agreed to by both houses of the Legislature, again without legal force to change state law.For stakeholders, the text matters not because it changes obligations but because it creates an official, time-bound occasion for organized outreach. Hospitals, specialty clinics, and advocacy groups will likely use the resolution’s existence to schedule events, publicize patient stories, coordinate screening and education efforts, and leverage media attention.
Researchers and clinical centers may cite legislative recognition in outreach materials and to justify awareness-driven recruitment for observational studies, but the resolution does not alter research funding mechanisms or regulatory oversight.
The Five Things You Need to Know
Sponsor and form: ACR 125 is an Assembly Concurrent Resolution introduced by Assemblymember Juan Alanis during the 2025–2026 regular session.
Medical recitals: The resolution’s ‘whereas’ clauses summarize clinical features, typical onset in adolescence/early adulthood, and common comorbidities such as syringomyelia and hydrocephalus.
Federal research referenced: The text explicitly cites work by the National Institute of Neurological Disorders and Stroke as ongoing research into causes and surgical options.
Procedural direction: The only operative instruction directs the Chief Clerk of the Assembly to transmit copies of the adopted resolution to the author for distribution.
No fiscal or regulatory change: The Legislative Counsel Digest notes a Fiscal Committee: NO — the measure contains no appropriation, mandate, or change to state law.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Medical background and rationale
This section collects factual recitals about Chiari malformation: historical identification, description of the anatomical defect, typical symptoms, ages of onset, and commonly associated conditions. Practically, these recitals justify the awareness designation by explaining health impacts and linking the condition to broader clinical concerns such as cerebrospinal fluid flow disruption and related spinal disorders.
Citation of federal research activity
One ‘whereas’ highlights research at the National Institutes of Health — specifically NINDS — focused on surgical alternatives and etiologic study. That citation signals alignment with federal research priorities but imposes no obligation on state agencies; it is a rhetorical bridge for advocates to reference when seeking collaboration with federal researchers or funders.
Legislative recognition and calendar placement
The resolved language provides the formal legislative acknowledgment — the mechanism by which the Legislature records its support for awareness efforts. Because it is a concurrent resolution, the clause reflects the legislature’s voice but does not create binding law, appropriations, or regulatory duties for state actors.
Transmission of copies for distribution
A short administrative provision directs the Chief Clerk to transmit copies of the resolution to the author. This is a standard closing clause for informational distribution; it creates a tangible record that the author can circulate to advocacy groups, hospitals, and local governments to coordinate events.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with Chiari malformation and their families — gain a state-sanctioned opportunity to increase public awareness, reduce stigma, and amplify requests for diagnostic and care resources.
- Patient advocacy organizations — obtain a legislative citation they can use in outreach, fundraising appeals, and to coordinate awareness events during the designated month.
- Clinical specialty centers and neurosurgery programs — receive a predictable calendar moment to host screenings, education sessions, and to recruit for registries or observational studies.
- Researchers and clinical trial teams — can reference legislative recognition when building community engagement strategies or letters of support for grant applications.
Who Bears the Cost
- Assembly administrative staff — small, routine printing and distribution duties associated with transmitting copies to the author; no new ongoing costs are created.
- Patient organizations and clinical partners — expected to supply the time, staffing, and fundraising necessary to turn awareness into programs; the resolution does not fund those activities.
- Local health departments or hospitals that choose to participate — may incur modest event and outreach costs if they elect to organize activities tied to the awareness month.
Key Issues
The Core Tension
The central dilemma is visibility versus substance: the bill offers recognition that can help advocacy and outreach, but because it provides no funding or mandates, it risks raising expectations without delivering the concrete resources or policy changes needed to improve diagnosis, care, or research capacity.
The resolution is purely symbolic and creates no funding, programmatic commitments, or regulatory changes; that boosts visibility but may also create misplaced expectations among constituents who assume legislative recognition includes material support. Because ACR 125 cites federal research at NINDS, advocates might conflate legislative recognition with enhanced research funding, but the resolution offers no pathway to alter NIH budgets or priorities.
Implementation in practice therefore depends entirely on private, nonprofit, and clinical actors translating the recognition into events, educational materials, or fundraising.
Another practical tension is calendar crowding: awareness months are numerous, and the marginal benefit of an additional designation depends on coordinated outreach, media buy-in, and measurable goals. Without guidance or funding, smaller patient groups risk shouldering outreach costs and may struggle to convert awareness into improved diagnosis rates or care access.
Finally, symbolic resolutions can be used by stakeholders as leverage in grant applications or institutional messaging — useful — but they can also trigger mismatched expectations among patients about immediate policy or service changes.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.